Results 171 to 180 of about 6,560 (205)

Molnupiravir/sotrovimab

Reactions Weekly, 2023
  +4 more sources

A tale of two drugs: Molnupiravir and Paxlovid

Mutation Research - Reviews in Mutation Research
The orally administered antiviral drug Lagevrio or molnupiravir (MOV) and the combination antiviral drug nirmatrelvir/ritonavir or Paxlovid (PAX) have been shown to reduce the likelihood of hospitalization and death for high-risk patients with COVID-19.
Michael D. Waters, Stafford G. Warren
openaire   +2 more sources

Immunosuppressants/molnupiravir

Reactions Weekly, 2023
openaire   +2 more sources

Molnupiravir: evidence by press release

Drug and Therapeutics Bulletin, 2021
James A Cave, David Phizackerley
openaire   +2 more sources

Molnupiravir in COVID-19: A systematic review of literature

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021
Awadhesh Kumar Singh, Akriti Singh, Anoop Misra   +2 more
exaly  

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

EBioMedicine, 2021
Rana Abdelnabi, Caroline S Foo, Suzanne J F Kaptein   +2 more
exaly  

Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis

Clinical Infectious Diseases, 2023
Ronza Najjar-Debbiny, Johad Khoury, Nili Stein   +2 more
exaly  

Molnupiravir

Reactions Weekly
  +4 more sources

Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023
Ahmed H Abdelazim, Mohammed A S Abourehab, Ahmed A Almrasy   +2 more
exaly